FY2023 · ended Dec 31, 2023 · Revenue $38.71M, +52.0% YoY · Filed Mar 31, 2025
Palvella Therapeutics, Inc. (PVLA) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $250.6 million in cash and investments and $535,000 in total debt.
Revenue (TTM)
$1.05M
-97.6% vs year-ago TTM
Net income (TTM)
$25.17M
+189.7% vs year-ago TTM
Operating cash flow (TTM)
$-36.51M
-79.5% vs year-ago TTM
Free cash flow
$-13.87M
+77.2% vs prior year
EPS
$-3.71
+52.6% vs prior year
Dividend per share
None
Shares outstanding
14.31M
+29.9% vs prior year
Net cash
$250.05M
as of Jun 30, 2026
Operating margin
347.6%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PVLA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Wayne, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1583648
- Former names
- PIERIS PHARMACEUTICALS, INC. (until Dec 12, 2024); Marika Inc. (until Dec 18, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $38.7M | $25.5M | $27.9M |
| Operating income | -$38.6M | -$14.1M | -$11.9M | -$43.5M | -$51.8M |
| Net income | -$41.7M | -$17.4M | $18.7M | -$33.3M | -$45.7M |
| Diluted EPS | -$3.71 | -$7.83 | — | — | -$0.71 |
| Operating cash flow | -$25.0M | -$10.8M | -$13.7M | -$59.9M | -$7.7M |
| Free cash flow | — | — | -$13.9M | -$61.0M | -$8.6M |
| Total assets | $59.6M | $88.2M | $7.5M | $95.5M | $153.6M |
| Total liabilities | $31.6M | $25.6M | $11.4M | $67.6M | $102.8M |
| Stockholders' equity | $28.0M | $62.6M | -$74.5M | -$93.8M | $50.8M |
| Cash and investments | $58.0M | $83.6M | $16.3M | $59.2M | $117.8M |
| Total debt | $633,000 | — | $0 | $13.1M | $14.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 28, 2026 | Oct 28, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Other events
|
Jul 14, 2026 | Jul 14, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 30, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 16, 2026 | Jun 10, 2026 |
All 814 Palvella Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.